© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
NEWS |
Early-Stage Lung Cancer Findings End a Debate, Put Focus on Next Steps
| The first 10% of the full text of this article appears below. |
New data have resolved one of oncology's long-standing debates: Adjuvant therapy in early-stage, nonsmall-cell lung cancer (NSCLC) does improve survival significantly and probably should become the standard of care, according to the findings of two major trials.
In one of the trials, led by the National Cancer Institute of Canada (NCIC), there was an absolute survival benefit of 15% after 5 years for patients receiving chemotherapy. In the other, led by the Cancer and Leukemia Group B (CALGB), the absolute benefit was 12% after 4 years.
"Our belief is that the findings will lead to changes in therapy," said Bruce Johnson, M.D., of Dana-Farber Cancer Institute, Boston, speaking at the June meeting of the American Society of Clinical Oncology (ASCO) in New Orleans, where the late-breaking abstracts were presented.
Katherine Pisters, M.D.,
Why the Difference?
Next Steps